Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Lori A. Leslie et al.|Blood|2023Cited by 47
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Michael J. Buege et al.|Blood|2022Cited by 20
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell LymphomaDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 1
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposureMwanasha H. Merrill, David Qualls, Robert Redd et al.|HemaSphere|2025Cited by 0